Cargando…

Single-arm trials for domestic oncology drug approvals in China

Detalles Bibliográficos
Autores principales:	Zhang, Hong, Liu, Sen, Ge, Chenghao, Liu, Xiaozhen, Liu, Yang, Yin, Chen, Li, Yi, An, Jing, Yan, Zhongtian, Chen, Xiaoyuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Compuscript 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10690876/ https://www.ncbi.nlm.nih.gov/pubmed/38013490 http://dx.doi.org/10.20892/j.issn.2095-3941.2023.0360

Ejemplares similares

Trends and Characteristics of New Drug Approvals in China, 2011–2021
por: Su, Ling, et al.
Publicado: (2022)

Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
por: Chabner, Bruce A.
Publicado: (2017)

Clinical pharmacology strategies in supporting drug development and approval of antibody–drug conjugates in oncology
por: Liu, Stephanie N., et al.
Publicado: (2021)

Response rate of anticancer drugs approved by the Food and Drug Administration based on a single-arm trial
por: Oda, Yoshihiro, et al.
Publicado: (2022)

Simultaneous development of zanubrutinib in the USA and China
por: Li, Guanqiao, et al.
Publicado: (2020)

Feasibility of Randomized Controlled Trials for Cancer Drugs Approved by the Food and Drug Administration Based on Single-Arm Studies
por: Rittberg, Rebekah, et al.
Publicado: (2021)

Statistical Considerations on the Use of RWD/RWE for Oncology Drug Approvals: Overview and Lessons Learned
por: Ro, Sunhee K., et al.
Publicado: (2023)

Criteria and regulatory considerations for the conditional approval of innovative antitumor drugs in China: from the perspective of clinical reviewers
por: Zou, Limin, et al.
Publicado: (2023)

International oncology drug approvals for multiregional or single-country clinical trials: A systematic review
por: Zhang, Min, et al.
Publicado: (2022)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Contemporary oncology trials, drug approvals and the physician-patient relationship
por: Schnog, John-John B., et al.
Publicado: (2022)

Clinical Trial Design and Drug Approval in Oncology: A Primer for the Advanced Practitioner in Oncology
por: Kurtin, Sandra E., et al.
Publicado: (2020)

Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013)

Flibanserin: Approval of a controversial drug for a controversial disorder
por: Sathyanarayana Rao, T. S., et al.
Publicado: (2015)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Prescription Drugs Marketed in the United States Should Be Approved by the FDA
por: Shepherd, Marvin
Publicado: (2003)

Immuno‐Oncology in China
por: Lu, Shun, et al.
Publicado: (2019)

Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
por: Blumenthal, Gideon M., et al.
Publicado: (2017)

Prucalopride: A Recently Approved Drug by the Food and Drug Administration for Chronic Idiopathic Constipation
por: Mahajan, Rajiv
Publicado: (2019)

New Results Will Change the Paradigm for Phase I Trials and Drug Approval
por: Chabner, Bruce A.
Publicado: (2010)

Fast-track pathways for drug approvals: the Australian experience so far
por: Bootes, Adrian, et al.
Publicado: (2019)

Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
por: Cicenas, Jonas, et al.
Publicado: (2021)

Genetic variation of nucleocapsid genes of porcine epidemic diarrhea virus field strains in China
por: Chen, Jianfei, et al.
Publicado: (2013)

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006–2021: a cross-sectional study
por: Xie, Jinping, et al.
Publicado: (2023)

Getting approval for new therapeutic medical devices versus drugs: are the differences justified?
por: Frigerio, Maria
Publicado: (2016)

Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries
por: Green, Angela K., et al.
Publicado: (2021)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
por: Tateo, Valentina, et al.
Publicado: (2023)

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022
por: Luo, Xingxian, et al.
Publicado: (2023)

Blood test to help diagnose type 1 diabetes approved by Food and Drug Administration
por: Mahajan, Rajiv
Publicado: (2015)

Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?
por: Shepshelovich, Daniel, et al.
Publicado: (2018)

Anticancer drug R&D landscape in China
por: Zhao, Shen, et al.
Publicado: (2020)

2015 Review of Newly Approved Oncologic Therapies
por: Medina, Patrick, et al.
Publicado: (2016)

Will the hydrogen therapy be approved shortly?
por: Ohta, Shigeo
Publicado: (2020)

Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021
por: Lau, Catherine, et al.
Publicado: (2022)

Screening of Natural Products and Approved Oncology Drug Libraries for Activity against Clostridioides difficile
por: Pal, Rusha, et al.
Publicado: (2020)

High-Throughput Screening of FDA-Approved Drug Library Reveals Ixazomib Is a Broad-Spectrum Antiviral Agent against Arboviruses
por: Ding, Cuiling, et al.
Publicado: (2022)

Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration
por: Hutchinson, Nora, et al.
Publicado: (2021)

Eribulin Approval in Advanced Liposarcoma – Successful Drug or a Weaker Methodology?
por: Rastogi, Sameer, et al.
Publicado: (2017)

The Continuing Impact of Oncology Drug Shortages
por: Viale, Pamela Hallquist
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_3i6g5rrvsknqprsmnoqb8j3i23